Araştırma Makalesi

Metformin Administration to Glucose-restricted Cells Attenuates PKA Signaling in S. cerevisiae

Cilt: 35 Sayı: 3 30 Eylül 2023
PDF İndir
EN TR

Metformin Administration to Glucose-restricted Cells Attenuates PKA Signaling in S. cerevisiae

Öz

Recent research in cancer treatment points to metformin, a drug for type 2 diabetes, as a potential anti-cancer therapeutic, as well as carbon limitation as a dietary measure. A new study, investigating effects of metformin treatment on colorectal cancer cells, pointed to the fact that response to metformin treatment depended on extracellular glucose concentration. That is why in the current study, effects of both carbon limitation and metformin treatment are explored via transcriptomics analyses. It is demonstrated that cells grown in glucose-limited and metformin treated medium had the highest variance according to transcriptional profiles, compared to individual treatments. Metformin administration, when combined with glucose restriction, downregulates proliferative pathways such as transcription initiation and ribosome biogenesis while upregulates energy derivation and autophagic mechanisms. Enrichment analyses point to an attenuated cAMP-PKA signaling pathway in the cells grown in combined treatment medium. It is proposed that combined treatment exerts its beneficial effect on this pathway, since cAMP-PKA signaling may be a potential target for pharmacological treatment of tumors.

Anahtar Kelimeler

Kaynakça

  1. [1] Warburg O, Wind F, Negelein E. (1927). The Metabolism of Tumors in the Body. J Gen Physiol. 7;8(6):519-30. doi: 10.1085/jgp.8.6.519. PMID: 19872213; PMCID: PMC2140820.
  2. [2] Elgendy M., Cirò M., Hosseini A., Weiszmann J., Mazzarella L., Ferrari E., Cazzoli R., Curigliano G., De Censi A., Bonanni B., et al. (2019). Combination of hypoglycemia and metformin impairs tumor metabolic plasticity and growth by modulating the PP2A-GSK3Β-MCL-1 axis. Cancer Cell. 35:798–815. doi: 10.1016/j.ccell.2019.03.007.
  3. [3] Di Tano M., Raucci F., Vernieri C., Caffa I., Buono R., Fanti M., Brandhorst S., Curigliano G., Nencioni A., de Braud F., et al. (2020) Synergistic effect of fasting-mimicking diet and vitamin C against KRAS mutated cancers. Nat. Commun. 11:2332–2342. doi: 10.1038/s41467-020-16243-3.
  4. [4] Wollen N, Bailey CJ. (1988). Inhibition of hepatic gluconeogenesis by metformin. Synergism with insulin. Biochem Pharmacol. 37(22):4353-8. doi: 10.1016/0006-2952(88)90617-x. PMID: 3058129.
  5. [5] Morales DR, Morris AD. (2015). Metformin in cancer treatment and prevention. Annu Rev Med. 66:17-29. doi: 10.1146/annurev-med-062613-093128. Epub 2014 Nov 6. PMID: 25386929.
  6. [6] Marini C, Cossu V, Bauckneht M, Lanfranchi F, Raffa S, Orengo AM, Ravera S, Bruno S, Sambuceti G. (2021). Metformin and Cancer Glucose Metabolism: At the Bench or at the Bedside? Biomolecules. 11(8):1231. doi: 10.3390/biom11081231. PMID: 34439897; PMCID: PMC8392176.
  7. [7] Alhourani AH, Tidwell TR, Bokil AA, Røsland GV, Tronstad KJ, Søreide K, Hagland HR. (2021). Metformin treatment response is dependent on glucose growth conditions and metabolic phenotype in colorectal cancer cells. Sci Rep. 11(1):10487. doi: 10.1038/s41598-021-89861-6. [8] Cazzanelli G, Pereira F, Alves S, Francisco R, Azevedo L, Dias Carvalho P, Almeida A, Côrte-Real M, Oliveira MJ, Lucas C, Sousa MJ, Preto A. (2018). The Yeast Saccharomyces cerevisiae as a Model for Understanding RAS Proteins and their Role in Human Tumorigenesis. Cells. 7(2):14. doi: 10.3390/cells7020014. PMID: 29463063; PMCID: PMC5850102.
  8. [9] Matuo R, Sousa FG, Soares DG, Bonatto D, Saffi J, Escargueil AE, Larsen AK, Henriques JA. (2012). Saccharomyces cerevisiae as a model system to study the response to anticancer agents. Cancer Chemother Pharmacol. 70(4):491-502. doi: 10.1007/s00280-012-1937-4. Epub 2012 Aug 1. PMID: 22851206.

Ayrıntılar

Birincil Dil

İngilizce

Konular

Mühendislik

Bölüm

Araştırma Makalesi

Erken Görünüm Tarihi

25 Eylül 2023

Yayımlanma Tarihi

30 Eylül 2023

Gönderilme Tarihi

22 Şubat 2023

Kabul Tarihi

18 Temmuz 2023

Yayımlandığı Sayı

Yıl 2023 Cilt: 35 Sayı: 3

Kaynak Göster

APA
Börklü, E. (2023). Metformin Administration to Glucose-restricted Cells Attenuates PKA Signaling in S. cerevisiae. International Journal of Advances in Engineering and Pure Sciences, 35(3), 322-330. https://doi.org/10.7240/jeps.1254802
AMA
1.Börklü E. Metformin Administration to Glucose-restricted Cells Attenuates PKA Signaling in S. cerevisiae. JEPS. 2023;35(3):322-330. doi:10.7240/jeps.1254802
Chicago
Börklü, Esra. 2023. “Metformin Administration to Glucose-restricted Cells Attenuates PKA Signaling in S. cerevisiae”. International Journal of Advances in Engineering and Pure Sciences 35 (3): 322-30. https://doi.org/10.7240/jeps.1254802.
EndNote
Börklü E (01 Eylül 2023) Metformin Administration to Glucose-restricted Cells Attenuates PKA Signaling in S. cerevisiae. International Journal of Advances in Engineering and Pure Sciences 35 3 322–330.
IEEE
[1]E. Börklü, “Metformin Administration to Glucose-restricted Cells Attenuates PKA Signaling in S. cerevisiae”, JEPS, c. 35, sy 3, ss. 322–330, Eyl. 2023, doi: 10.7240/jeps.1254802.
ISNAD
Börklü, Esra. “Metformin Administration to Glucose-restricted Cells Attenuates PKA Signaling in S. cerevisiae”. International Journal of Advances in Engineering and Pure Sciences 35/3 (01 Eylül 2023): 322-330. https://doi.org/10.7240/jeps.1254802.
JAMA
1.Börklü E. Metformin Administration to Glucose-restricted Cells Attenuates PKA Signaling in S. cerevisiae. JEPS. 2023;35:322–330.
MLA
Börklü, Esra. “Metformin Administration to Glucose-restricted Cells Attenuates PKA Signaling in S. cerevisiae”. International Journal of Advances in Engineering and Pure Sciences, c. 35, sy 3, Eylül 2023, ss. 322-30, doi:10.7240/jeps.1254802.
Vancouver
1.Esra Börklü. Metformin Administration to Glucose-restricted Cells Attenuates PKA Signaling in S. cerevisiae. JEPS. 01 Eylül 2023;35(3):322-30. doi:10.7240/jeps.1254802